Abstract
Lactobacillus gasseri TMC0356 (TMC0356), a probiotic strain originally isolated from the human intestine, was tested for its anti-tumor activities in vivo in murine tumor models. Oral administration of TMC0356 characteristically inhibited the growth of sarcoma S-180 (S-180) and hepatoma H22 (H22) cells, which had been implanted in mice. Serum gamma interferon was significantly enhanced during TMC0356 administration of 1,000 mg/kg in S-180-bearing mice (p<0.01). Serum levels of tumor necrosis factor-α and interleukin-18 were also altered, though these changes were not statistically significant. These results indicate that the anti-tumor effects of TMC0356 might, at least in part, arise from the impact of this bacterium on cell-mediated immunity in host animals.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
